Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome (IMAGINE-II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02117713
Recruitment Status : Completed
First Posted : April 21, 2014
Results First Posted : June 22, 2021
Last Update Posted : July 1, 2021
Sponsor:
Collaborators:
Lumena Pharmaceuticals, Inc.
Childhood Liver Disease Research and Education Network
Information provided by (Responsible Party):
Mirum Pharmaceuticals, Inc.

Brief Summary:
This is a multicentre, extension study of LUM001 in children diagnosed with Alagille Syndrome who have completed participation in a core LUM001 treatment protocol. The primary objective is to evaluate long-term safety and tolerability of LUM001. Efficacy will be assessed by evaluating the effect of LUM001 on the biochemical markers and pruritus associated with Alagille Syndrome.

Condition or disease Intervention/treatment Phase
Alagille Syndrome Drug: LUM001 (Maralixibat) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
Actual Study Start Date : March 16, 2015
Actual Primary Completion Date : June 1, 2020
Actual Study Completion Date : June 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Diseases

Arm Intervention/treatment
Experimental: LUM001 (Maralixibat)
Participant will receive LUM001 also known as Maralixibat (MRX) administered orally once per day.
Drug: LUM001 (Maralixibat)
Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 280 micrograms per kilogram (mcg/kg).




Primary Outcome Measures :
  1. Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA) [ Time Frame: Baseline to Week 48 ]
    This primacy efficacy endpoint is the mean change from MRX baseline to week 48 in fasting sBA levels.


Secondary Outcome Measures :
  1. Change From MRX Baseline to Week 216 in Fasting Serum Bile Acid (sBA) [ Time Frame: Baseline to week 216 ]
    The secondary endpoint of this study was the mean change from MRX baseline to week 216 fasting in sBA levels.

  2. Change From Baseline to Week 218 in Pruritus [ Time Frame: Baseline to Week 218 ]
    This secondary efficacy endpoint is the mean change from MRX baseline over time to week 218 in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe). Results reported here are the long-term results.

  3. Change From Baseline to Week 216 in Alanine Aminotransferase [ Time Frame: Baseline to week 216 ]
    This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALT levels.

  4. Change From Baseline to End of Treatment in Alkaline Phosphatase [ Time Frame: Baseline to Week 216 ]
    This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALP levels.

  5. Change From MRX Baseline to Week 216 in Aspartate Aminotransferase [ Time Frame: Baseline to week 216 ]
    This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in AST levels.

  6. Change From MRX Baseline to Week 216 in Clinician Xanthoma Severity Score [ Time Frame: Baseline to week 216 ]
    This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the lesions interfere or limit activities. Clinician xanthoma severity scores range from 0 to 4, with a score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling.

  7. Change From Baseline to Week 216/LOFC Clinician Scratch Scale (CSS) Score [ Time Frame: Baseline to Week 216 ]
    This secondary efficacy endpoint is the mean change from MRX baseline over time to week 216/LOCF in pruritus as measured by the Clinician Scratch Scale (CSS). The Clinician Scratch Scale uses a 5-point scale, where 0 = none; 1 = rubbing or mild scratching when undistracted; 2 = active scratching without evident skin abrasions; 3 = abrasion evident; 4 = cutaneous mutilation, haemorrhage and scarring evident.

  8. Change From MRX Baseline to Week 216 in Gamma Glutamyltransferase [ Time Frame: Baseline to Week 216 ]
    This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in GGT.

  9. Mean Change From MRX Baseline to Week 216 in Total Bilirubin [ Time Frame: Baseline to week 216 ]
    This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in total bilirubin.

  10. Mean Change From MRX Baseline to Week 216 in Direct Bilirubin [ Time Frame: Baseline to week 216 ]
    This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in direct bilirubin.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female, 12 months to 18 years of age.
  2. Competent to provide informed consent and assent (per institutional review board/Ethics Committee [IRB/EC]), as appropriate.
  3. Completed participation in the LUM001-301 protocol.
  4. Females of childbearing potential must have a negative urine pregnancy test [beta human chorionic gonadotropin (beta-hCG)] at the Baseline Visit.
  5. Sexually active females must be prepared to use an effective method of contraception during the trial.

    Effective methods of contraception are considered to be:

    1. Hormonal (for example, contraceptive pill, patch, intramuscular implant or injection); or
    2. Barrier method, for example, (a) condom with spermicide, or (b) diaphragm, with spermicide; or
    3. Intrauterine device (IUD).
  6. Participants above the age of assent and caregivers and children must be able to read and understand English or Spanish.
  7. Caregivers (and age appropriate participants) must have access to phone for scheduled calls from study site.
  8. Caregivers (and age appropriate participants) must be willing and able to complete a daily electronic diary (ItchRO) during the first consecutive 12 weeks of the study and then for 4 consecutive weeks following the Week 24 and Week 44 visits.
  9. Caregivers (and age appropriate participants) must digitally accept the licensing agreement in the ItchRO electronic diary software at the outset of the study.
  10. Eligible participants must be able to adhere to local Ethics Committee or Institutional Review Board (IRB) blood volume limits for laboratory testing.
  11. The participant has completed the protocol either through Week 144, or the End of Trial visit, or has received permission from the sponsor and the Premier Medical monitor to re-enter the study in the long-term, optional follow-up treatment period 2.
  12. Females of child-bearing potential must have a negative urine or serum pregnancy test (beta-HCG]) at the time of entry into the long-term optional follow-up treatment period 2.
  13. Male and female participants of child-bearing potential who are sexually active, or are not currently sexually active, but become sexually active during the study or for 30 days following the last dose of study drug, must agree to use acceptable contraception during the study.
  14. Informed consent and assent (per IRB/EC) as appropriate.
  15. Caregivers (and age appropriate participants) must have access to phone for scheduled calls from study site.
  16. Caregivers (and age appropriate participants) must be willing to follow the rules of eDiary completion.

Exclusion Criteria:

  1. Experienced an adverse event or serious adverse event (SAE) related to the study drug during the LUM001-301 protocol that led to the discontinuation of the participant from the core study.
  2. Any conditions or abnormalities (including laboratory abnormalities) which in the opinion of the Investigator, Medical Monitor or ChiLDReN Protocol Chair, may compromise the safety of the participant, or interfere with the participant participating in or completing the study.
  3. History or known presence of gallstones or kidney stones.
  4. History of non-adherence during the participant's participation in the LUM001-301 protocol. Non-adherence is defined by dosing compliance (dosing compliance is calculated by [the total number of doses that were actually taken by the participant] divided by [the total number of doses that should have been taken by the participant] multiplied by 100) of less than 80% in the LUM001-301 protocol.
  5. Unlikely to comply with the study protocol, or unsuitable for any other reason, as judged by the investigator.
  6. All above exclusion criteria will apply upon re-entry into the long-term, optional follow-up treatment period 2.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02117713


Locations
Layout table for location information
United States, California
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
University of California at San Francisco Children's Hospital
San Francisco, California, United States, 94143
United States, Colorado
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
United States, Indiana
Riley Hospital for Children
Indianapolis, Indiana, United States, 46202
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
United States, Pennsylvania
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19147
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States, 15224
United States, Texas
Baylor College of Medicine/Texas Children's Hospital
Houston, Texas, United States, 77030
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84113
United States, Washington
Seattle Children's Hospital
Seattle, Washington, United States, 98105
Canada, Ontario
The Hospital for Sick Children
Toronto, Ontario, Canada, M5G 1X8
Sponsors and Collaborators
Mirum Pharmaceuticals, Inc.
Lumena Pharmaceuticals, Inc.
Childhood Liver Disease Research and Education Network
Investigators
Layout table for investigator information
Study Director: Study Director Mirum
  Study Documents (Full-Text)

Documents provided by Mirum Pharmaceuticals, Inc.:
Study Protocol  [PDF] May 13, 2019
Statistical Analysis Plan  [PDF] April 9, 2020

Layout table for additonal information
Responsible Party: Mirum Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02117713    
Other Study ID Numbers: LUM001-305
SHP625-305 ( Other Identifier: Shire )
First Posted: April 21, 2014    Key Record Dates
Results First Posted: June 22, 2021
Last Update Posted: July 1, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Alagille Syndrome
Syndrome
Disease
Pathologic Processes
Digestive System Diseases
Cholestasis, Intrahepatic
Cholestasis
Bile Duct Diseases
Biliary Tract Diseases
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Abnormalities, Multiple
Congenital Abnormalities
Genetic Diseases, Inborn